KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Other Non-Current Liabilities (2016 - 2025)

CRISPR Therapeutics AG's Other Non-Current Liabilities history spans 11 years, with the latest figure at $6.1 million for Q4 2025.

  • For Q4 2025, Other Non-Current Liabilities rose 78.34% year-over-year to $6.1 million; the TTM value through Dec 2025 reached $6.1 million, up 78.34%, while the annual FY2025 figure was $6.1 million, 78.34% up from the prior year.
  • Other Non-Current Liabilities for Q4 2025 was $6.1 million at CRISPR Therapeutics AG, up from $5.3 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $8.7 million in Q2 2021 and bottomed at $958000.0 in Q4 2023.
  • The 5-year median for Other Non-Current Liabilities is $5.4 million (2023), against an average of $5.4 million.
  • The largest annual shift saw Other Non-Current Liabilities crashed 83.95% in 2023 before it surged 259.5% in 2024.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $7.3 million in 2021, then fell by 18.67% to $6.0 million in 2022, then plummeted by 83.95% to $958000.0 in 2023, then soared by 259.5% to $3.4 million in 2024, then skyrocketed by 78.34% to $6.1 million in 2025.
  • Per Business Quant, the three most recent readings for CRSP's Other Non-Current Liabilities are $6.1 million (Q4 2025), $5.3 million (Q3 2025), and $4.5 million (Q2 2025).